Učitavanje...
The role of B cells in multiple sclerosis: current and future therapies
While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab, a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated...
Spremljeno u:
| Izdano u: | Cell Immunol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6540809/ https://ncbi.nlm.nih.gov/pubmed/31130183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellimm.2018.10.006 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|